Exome Asset Management LLC
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Exome Asset Management LLC reported 58 stock positions worth $132.9 million. Its top holding was Bridgebio Pharma (BBIO) at 5.1% of the portfolio, followed by Eli Lilly (LLY, 4.8%) and Geron (GERN, 4.2%). Compared with Q3 2024, it opened 23 new positions, sold out of 24, added to 11 and reduced 18. The biggest buy was a new position in Humana (HUM) and the biggest sale an exit from Ascendis Pharma A/S (ASND).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0002011932
- Portfolio Value
- $132.9M (Q4 2024)
- SEC Filing
- 0001420506-25-000519 ↗ filed Feb 14, 2025
Holdings Value
Holdings 58 stocks · $132.9M
| BBIO Bridgebio Pharma Inc. | 5.09% | 246,700 | $6.8M | Add +16.9% |
| LLY Eli Lilly & Co. | 4.79% | 8,247 | $6.4M | Reduce -21.1% |
| GERN Geron Corp. | 4.23% | 1,561,152 | $5.6M | Add +72.5% |
| HUM Humana Inc. | 3.45% | 18,066 | $4.6M | New |
| GH Guardant Health Inc. | 3.40% | 147,800 | $4.5M | Add +64.6% |
| RLAY Relay Therapeutics Inc. | 3.36% | 1,083,487 | $4.5M | Add +161.3% |
| IRON Disc Medicine Inc. | 3.29% | 69,072 | $4.4M | Add +7.1% |
| SNDX Syndax Pharmaceuticals Inc. | 3.17% | 318,900 | $4.2M | New |
| ARVN Arvinas Inc. | 3.15% | 218,700 | $4.2M | New |
| GPCR Structure Therapeutics Inc. | 3.10% | 151,965 | $4.1M | Add +26.5% |
| ISRG Intuitive Surgical Inc. | 2.92% | 7,427 | $3.9M | No change |
| APLS Apellis Pharmaceuticals Inc. | 2.87% | 119,467 | $3.8M | Add +19.0% |
| BMY Bristol-Myers Squibb Co. | 2.77% | 65,200 | $3.7M | Reduce -16.4% |
| BSX Boston Scientific Corp. | 2.72% | 40,500 | $3.6M | New |
| NTRA Natera Inc. | 2.67% | 22,450 | $3.6M | No change |
| SLNO Soleno Therapeutics Inc. | 2.61% | 77,285 | $3.5M | New |
| SRRK Scholar Rock Holding Corp. | 2.52% | 77,439 | $3.3M | Reduce -41.8% |
| NUVL Nuvalent Inc. Class A | 2.40% | 40,580 | $3.2M | Add +103.5% |
| CYTK Cytokinetics Inc. | 2.33% | 65,883 | $3.1M | Add +12.5% |
| BPMC Blueprint Medicines Corp. | 2.09% | 31,800 | $2.8M | Reduce -13.3% |
| GILD Gilead Sciences Inc. | 2.06% | 29,700 | $2.7M | Reduce -40.6% |
| SMMT Summit Therapeutics Inc. | 1.75% | 130,412 | $2.3M | New |
| CNTA Centessa Pharmaceuticals Ltd. | 1.74% | 137,716 | $2.3M | Reduce -0.3% |
| EWTX Edgewise Therapeutics Inc. | 1.64% | 81,473 | $2.2M | Add +36.0% |
| JANX Janux Therapeutics Inc. | 1.62% | 40,123 | $2.1M | New |
| SVRA Savara Inc. | 1.62% | 699,698 | $2.1M | New |
| IONS Ionis Pharmaceuticals Inc. | 1.61% | 61,367 | $2.1M | New |
| PEN Penumbra Inc. | 1.61% | 9,000 | $2.1M | New |
| RCKT Rocket Pharmaceuticals Inc. | 1.51% | 159,552 | $2.0M | New |
| AKRO Akero Therapeutics Inc. | 1.44% | 68,608 | $1.9M | Reduce -11.0% |
| RDY Dr. Reddy's Laboratories-ADR | 1.40% | 117,500 | $1.9M | Reduce -35.3% |
| ONC Beone Medicines Ltd.-ADR filed as BEIGENE LTD | 1.39% | 10,000 | $1.8M | Reduce -34.6% |
| ETNB 89BIO Inc. | 1.33% | 225,323 | $1.8M | Reduce -25.0% |
| TARS Tarsus Pharmaceuticals Inc. | 1.17% | 28,178 | $1.6M | Reduce -38.2% |
| KARYOPHARM THERAPEUTICS (KPTI 3 10/15/25) | 1.17% | 2,000,000 | $1.6M | No change |
| PLRX Pliant Therapeutics Inc. | 1.03% | 103,504 | $1.4M | Reduce -30.8% |
| FULC Fulcrum Therapeutics Inc. | 1.00% | 283,599 | $1.3M | New |
| STOK Stoke Therapeutics Inc. | 0.94% | 113,096 | $1.2M | Reduce -36.0% |
| LEGN Legend Biotech Corp.-ADR | 0.92% | 37,600 | $1.2M | Reduce -20.0% |
| TECX Tectonic Therapeutic Inc. | 0.91% | 26,081 | $1.2M | Reduce -28.2% |
| ALVO Alvotech SA | 0.90% | 90,100 | $1.2M | No change |
| VYNE THERAPEUTICS INC | 0.89% | 353,434 | $1.2M | No change |
| ELDN Eledon Pharmaceuticals Inc. | 0.79% | 256,373 | $1.1M | New |
| BHVN Biohaven Ltd. | 0.79% | 28,159 | $1.1M | New |
| GOSS Gossamer Bio Inc. | 0.75% | 1,097,999 | $993K | Add +134.4% |
| ACRS Aclaris Therapeutics Inc. | 0.73% | 389,333 | $966K | New |
| ANNX Annexon Inc. | 0.56% | 144,830 | $743K | New |
| VERU Veru Inc. | 0.56% | 1,117,600 | $740K | New |
| SLRN Acelyrin Inc. | 0.55% | 234,435 | $736K | New |
| REPL Replimune Group Inc. | 0.50% | 54,738 | $663K | New |
| ESTA Establishment Labs Holdings | 0.45% | 13,100 | $604K | Reduce -39.6% |
| NKTR Nektar Therapeutics | 0.43% | 618,174 | $575K | New |
| APRE Aprea Therapeutics Inc. | 0.32% | 127,960 | $420K | Reduce -6.7% |
| AKBA Akebia Therapeutics Inc. | 0.29% | 205,956 | $391K | New |
| MDGL Madrigal Pharmaceuticals Inc. | 0.23% | 987 | $305K | New |
| CYPH Cypherpunk Technologies Inc. filed as LEAP THERAPEUTICS INC | 0.22% | 102,631 | $295K | No change |
| MERSANA THERAPEUTICS INC | 0.19% | 172,924 | $250K | Reduce -85.3% |
| ABUS Arbutus Biopharma Corp. | 0.07% | 28,300 | $93K | New |
Options reported separately and not counted above: NEUMORA THERAPEUTICS INC. calls ($207K).
Portfolio Sells Q3 2024 → Q4 2024
| ASND Ascendis Pharma A/S | Sold out | 0.00% | −4.43 |
| TGTX TG Therapeutics Inc. | Sold out | 0.00% | −3.28 |
| ALGN Align Technology Inc. | Sold out | 0.00% | −3.21 |
| CI The Cigna Group | Sold out | 0.00% | −2.86 |
| BNTX Biontech SE-ADR | Sold out | 0.00% | −2.77 |
| VRDN Viridian Therapeutics Inc. | Sold out | 0.00% | −2.68 |
| GKOS Glaukos Corp. | Sold out | 0.00% | −2.28 |
| SWTX Springworks Therapeutics Inc. | Sold out | 0.00% | −2.18 |
| AGIO Agios Pharmaceuticals Inc. | Sold out | 0.00% | −1.99 |
| BIIB Biogen Inc. | Sold out | 0.00% | −1.74 |
| INSM Insmed Inc. | Sold out | 0.00% | −1.66 |
| LLY Eli Lilly & Co. | Reduce -21.1% | 4.79% | −1.47 |
| AMGN Amgen Inc. | Sold out | 0.00% | −1.46 |
| MERSANA THERAPEUTICS INC | Reduce -85.3% | 0.19% | −1.32 |
| RVNC Revance Therapeutics Inc. | Sold out | 0.00% | −1.22 |
| KURA Kura Oncology Inc. | Sold out | 0.00% | −1.19 |
| RZLT Rezolute Inc. | Sold out | 0.00% | −1.15 |
| STAA Staar Surgical Co. | Sold out | 0.00% | −1.02 |
| BCRX Biocryst Pharmaceuticals Inc. | Sold out | 0.00% | −1.01 |
| ONC Beone Medicines Ltd.-ADR | Reduce -34.6% | 1.39% | −0.93 |
| GILD Gilead Sciences Inc. | Reduce -40.6% | 2.06% | −0.77 |
| QTRX Quanterix Corp. | Sold out | 0.00% | −0.64 |
| LEGN Legend Biotech Corp.-ADR | Reduce -20.0% | 0.92% | −0.63 |
| RDY Dr. Reddy's Laboratories-ADR | Reduce -35.3% | 1.40% | −0.55 |
| ACRV Acrivon Therapeutics Inc. | Sold out | 0.00% | −0.55 |
| LXEO Lexeo Therapeutics Inc. | Sold out | 0.00% | −0.54 |
| STOK Stoke Therapeutics Inc. | Reduce -36.0% | 0.94% | −0.53 |
| SYRS Syros Pharmaceuticals Inc. | Sold out | 0.00% | −0.43 |
| ADAG Adagene Inc.-ADR | Sold out | 0.00% | −0.39 |
| BPMC Blueprint Medicines Corp. | Reduce -13.3% | 2.09% | −0.21 |
| PROCF Sofgen Pharma SA | Sold out | 0.00% | −0.19 |
| ESTA Establishment Labs Holdings | Reduce -39.6% | 0.45% | −0.18 |
| ETNB 89BIO Inc. | Reduce -25.0% | 1.33% | −0.18 |
| PLRX Pliant Therapeutics Inc. | Reduce -30.8% | 1.03% | −0.11 |
| PACB Pacific Biosciences of Calif | Sold out | 0.00% | −0.09 |
| AKRO Akero Therapeutics Inc. | Reduce -11.0% | 1.44% | −0.06 |
| BMY Bristol-Myers Squibb Co. | Reduce -16.4% | 2.77% | +0.05 |
| APRE Aprea Therapeutics Inc. | Reduce -6.7% | 0.32% | +0.06 |
| TARS Tarsus Pharmaceuticals Inc. | Reduce -38.2% | 1.17% | +0.16 |
| TECX Tectonic Therapeutic Inc. | Reduce -28.2% | 0.91% | +0.16 |
| CNTA Centessa Pharmaceuticals Ltd. | Reduce -0.3% | 1.74% | +0.24 |
| SRRK Scholar Rock Holding Corp. | Reduce -41.8% | 2.52% | +1.76 |
Portfolio Buys Q3 2024 → Q4 2024
| HUM Humana Inc. | New | 3.45% | +3.45 |
| SNDX Syndax Pharmaceuticals Inc. | New | 3.17% | +3.17 |
| ARVN Arvinas Inc. | New | 3.15% | +3.15 |
| BSX Boston Scientific Corp. | New | 2.72% | +2.72 |
| SLNO Soleno Therapeutics Inc. | New | 2.61% | +2.61 |
| GH Guardant Health Inc. | Add +64.6% | 3.40% | +2.00 |
| SMMT Summit Therapeutics Inc. | New | 1.75% | +1.75 |
| JANX Janux Therapeutics Inc. | New | 1.62% | +1.62 |
| SVRA Savara Inc. | New | 1.62% | +1.62 |
| IONS Ionis Pharmaceuticals Inc. | New | 1.61% | +1.61 |
| PEN Penumbra Inc. | New | 1.61% | +1.61 |
| RCKT Rocket Pharmaceuticals Inc. | New | 1.51% | +1.51 |
| BBIO Bridgebio Pharma Inc. | Add +16.9% | 5.09% | +1.46 |
| GERN Geron Corp. | Add +72.5% | 4.23% | +1.45 |
| RLAY Relay Therapeutics Inc. | Add +161.3% | 3.36% | +1.37 |
| IRON Disc Medicine Inc. | Add +7.1% | 3.29% | +1.15 |
| NUVL Nuvalent Inc. Class A | Add +103.5% | 2.40% | +1.02 |
| FULC Fulcrum Therapeutics Inc. | New | 1.00% | +1.00 |
| APLS Apellis Pharmaceuticals Inc. | Add +19.0% | 2.87% | +0.91 |
| ELDN Eledon Pharmaceuticals Inc. | New | 0.79% | +0.79 |
| BHVN Biohaven Ltd. | New | 0.79% | +0.79 |
| ACRS Aclaris Therapeutics Inc. | New | 0.73% | +0.73 |
| ANNX Annexon Inc. | New | 0.56% | +0.56 |
| VERU Veru Inc. | New | 0.56% | +0.56 |
| EWTX Edgewise Therapeutics Inc. | Add +36.0% | 1.64% | +0.56 |
| SLRN Acelyrin Inc. | New | 0.55% | +0.55 |
| REPL Replimune Group Inc. | New | 0.50% | +0.50 |
| GOSS Gossamer Bio Inc. | Add +134.4% | 0.75% | +0.43 |
| NKTR Nektar Therapeutics | New | 0.43% | +0.43 |
| AKBA Akebia Therapeutics Inc. | New | 0.29% | +0.29 |
| CYTK Cytokinetics Inc. | Add +12.5% | 2.33% | +0.24 |
| MDGL Madrigal Pharmaceuticals Inc. | New | 0.23% | +0.23 |
| ABUS Arbutus Biopharma Corp. | New | 0.07% | +0.07 |
| GPCR Structure Therapeutics Inc. | Add +26.5% | 3.10% | −0.46 |
Options Activity Q3 2024 → Q4 2024
| NEUMORA THERAPEUTICS INC. | call | New | 600 | $207K |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 52 | $162.1M | GH, PRAX, TGTX, COGT, IONS |
| Q1 2026 | 45 | $169.9M | PRAX, COGT, ELVN, IONS, GH |
| Q4 2025 | 53 | $202.4M | PRAX, COGT, GH, IONS, LLY |
| Q3 2025 | 54 | $151.4M | IONS, CYTK, BBIO, COGT, GH |
| Q2 2025Amended | 55 | $121.3M | ISHARES TR, BBIO, GH, GERN, IONS |
| Q1 2025Amended | 49 | $111.6M | BBIO, GH, GERN, AZN, CYTK |
| Q4 2024 | 58 | $132.9M | BBIO, LLY, GERN, HUM, GH |
| Q3 2024Amended | 59 | $147.9M | LLY, ASND, BBIO, GPCR, TGTX |
| Q2 2024Amended | 52 | $112.3M | LLY, SRPT, ONC, TGTX, CI |
| Q1 2024 | 53 | $116.8M | LLY, RDY, ONC, CI, ALPN |